胃肠外科

订阅

MedSci主页 / 所有栏目 / 胃肠外科

GUT：手术或英利昔单抗治疗克罗恩病成本效应研究

2019-02-02 zhangfan MedSci原创

克罗恩病腹腔镜回肠切除英利昔单抗
关注

腹腔镜回肠切除治疗回肠克罗恩病的成本效果优于英利昔单抗

近日研究人员比较了腹腔镜回肠切除与英利昔单抗治疗回肠克罗恩病的成本效果。

成人回肠末端克罗恩病患者参与研究，常规免疫调节剂或类固醇治疗失败3个月以上，无严重狭窄征象，随机接受腹腔镜回肠切除或英利昔单抗治疗。研究的主要终点为EuroQol(EQ)5D-3L以及炎症性肠病问卷(IBDQ)评估的质量调整寿命(QALYs)。

143名患者参与研究，手术组平均克罗恩病患者1年直接医疗费用总额低于英利昔单抗组（平均差异8931欧），总社会成本较低，但差异不显著（平均差异5729欧）。与英利昔单抗相比，切除组QALY和IBDQ得分提高的花费指示(WTP)在0.96-0.99之间，成本效应更为显著。

研究认为，腹腔镜回肠切除治疗回肠克罗恩病的成本效果优于英利昔单抗。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1559899, encodeId=0e471559899e0, content=<a href='/topic/show?id=81658e0779d' target=_blank style='color:#2F92EE;'>#英利昔单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87077, encryptionId=81658e0779d, topicName=英利昔单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=589415038604, createdName=bnjfx@131.com, createdTime=Mon Feb 04 01:15:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565908, encodeId=1e0715659088a, content=<a href='/topic/show?id=81658e0779d' target=_blank style='color:#2F92EE;'>#英利昔单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87077, encryptionId=81658e0779d, topicName=英利昔单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=589415038604, createdName=bnjfx@131.com, createdTime=Mon Feb 04 01:15:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359878, encodeId=d6da3598e82a, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 03 11:12:09 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359838, encodeId=fc223598386e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9612542194, createdName=12523ac1m54暂无昵称, createdTime=Sat Feb 02 20:31:39 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359835, encodeId=1ab0359835b2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Feb 02 19:52:43 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-04 bnjfx@131.com

    #英利昔单抗#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1559899, encodeId=0e471559899e0, content=<a href='/topic/show?id=81658e0779d' target=_blank style='color:#2F92EE;'>#英利昔单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87077, encryptionId=81658e0779d, topicName=英利昔单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=589415038604, createdName=bnjfx@131.com, createdTime=Mon Feb 04 01:15:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565908, encodeId=1e0715659088a, content=<a href='/topic/show?id=81658e0779d' target=_blank style='color:#2F92EE;'>#英利昔单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87077, encryptionId=81658e0779d, topicName=英利昔单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=589415038604, createdName=bnjfx@131.com, createdTime=Mon Feb 04 01:15:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359878, encodeId=d6da3598e82a, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 03 11:12:09 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359838, encodeId=fc223598386e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9612542194, createdName=12523ac1m54暂无昵称, createdTime=Sat Feb 02 20:31:39 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359835, encodeId=1ab0359835b2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Feb 02 19:52:43 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-04 bnjfx@131.com

    #英利昔单抗#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1559899, encodeId=0e471559899e0, content=<a href='/topic/show?id=81658e0779d' target=_blank style='color:#2F92EE;'>#英利昔单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87077, encryptionId=81658e0779d, topicName=英利昔单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=589415038604, createdName=bnjfx@131.com, createdTime=Mon Feb 04 01:15:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565908, encodeId=1e0715659088a, content=<a href='/topic/show?id=81658e0779d' target=_blank style='color:#2F92EE;'>#英利昔单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87077, encryptionId=81658e0779d, topicName=英利昔单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=589415038604, createdName=bnjfx@131.com, createdTime=Mon Feb 04 01:15:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359878, encodeId=d6da3598e82a, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 03 11:12:09 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359838, encodeId=fc223598386e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9612542194, createdName=12523ac1m54暂无昵称, createdTime=Sat Feb 02 20:31:39 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359835, encodeId=1ab0359835b2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Feb 02 19:52:43 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-03 1e145228m78(暂无匿称)

    学习了，谢谢作者分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1559899, encodeId=0e471559899e0, content=<a href='/topic/show?id=81658e0779d' target=_blank style='color:#2F92EE;'>#英利昔单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87077, encryptionId=81658e0779d, topicName=英利昔单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=589415038604, createdName=bnjfx@131.com, createdTime=Mon Feb 04 01:15:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565908, encodeId=1e0715659088a, content=<a href='/topic/show?id=81658e0779d' target=_blank style='color:#2F92EE;'>#英利昔单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87077, encryptionId=81658e0779d, topicName=英利昔单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=589415038604, createdName=bnjfx@131.com, createdTime=Mon Feb 04 01:15:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359878, encodeId=d6da3598e82a, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 03 11:12:09 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359838, encodeId=fc223598386e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9612542194, createdName=12523ac1m54暂无昵称, createdTime=Sat Feb 02 20:31:39 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359835, encodeId=1ab0359835b2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Feb 02 19:52:43 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-02 12523ac1m54暂无昵称

    挺好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1559899, encodeId=0e471559899e0, content=<a href='/topic/show?id=81658e0779d' target=_blank style='color:#2F92EE;'>#英利昔单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87077, encryptionId=81658e0779d, topicName=英利昔单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=589415038604, createdName=bnjfx@131.com, createdTime=Mon Feb 04 01:15:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565908, encodeId=1e0715659088a, content=<a href='/topic/show?id=81658e0779d' target=_blank style='color:#2F92EE;'>#英利昔单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87077, encryptionId=81658e0779d, topicName=英利昔单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=589415038604, createdName=bnjfx@131.com, createdTime=Mon Feb 04 01:15:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359878, encodeId=d6da3598e82a, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 03 11:12:09 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359838, encodeId=fc223598386e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9612542194, createdName=12523ac1m54暂无昵称, createdTime=Sat Feb 02 20:31:39 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359835, encodeId=1ab0359835b2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Feb 02 19:52:43 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-02 1e145228m78(暂无匿称)

    学习了，谢谢作者分享!

    0

相关资讯

2019 SNFCP国家共识：克罗恩病肛门会阴病变的管理

2019年1月，法国国家结直肠病学学会(SNFCP)发布了克罗恩病肛门会阴病变的管理共识，主要内容涉及急性脓肿，活动瘘，缓解期瘘，以及直肠阴道瘘的管理。

错综复杂丨与克罗恩病和溃疡性结肠炎极其相似的三种肠病

简女士60岁时，因为持续半年的严重腹泻生活发生了重大变化。她每天上厕所的次数达12次之多，连晚上都得爬起来上厕所。

Inflamm Bowel Dis：英夫利西单抗治疗克罗恩病，不同治疗目标，不同血药浓度

英夫利西单抗是一种抗肿瘤坏死因子（抗-TNF）药物，常用来治疗中度至重度克罗恩病（CD）。

中国克罗恩病并发肠瘘诊治的专家共识意见

克罗恩病是累及消化道全层的慢性炎性疾病，肠瘘是其最为严重的外科并发症。治疗目标是治愈肠瘘与腹腔感染、恢复消化道的连续性、减少术后复发和改善生活质量。临床上应对克罗恩病并发的肠瘘进行充分评估，努力促进肠瘘的自行愈合，联合肠内营养与外科引流有助于促进肠瘘自行愈合。同时要重视围手术期营养状况的评估，并给予营养支持治疗。合并的腹腔脓肿建议使用Trocar穿刺置双套管建立主动冲洗引流.药物、营养治疗以及外科

CLIN CANCER RES：克罗恩病相关结直肠肿瘤发生的基因改变情况

炎症性肠病患者（溃疡性结肠炎和克罗恩病（CD））患结直肠癌（CRC）的风险增加。溃疡性结肠炎研究的证据表明，TP53突变代表了从炎症结肠上皮向CRC发展的第一步。然而，CD患者向CRC的演变机制尚不清楚。CLIN CANCER RES近期发表了一篇文章研究这一问题。

Clin Gastroenterol H：内镜下扩张胃十二指肠克罗恩病狭窄的疗效

由此可见，在这项荟萃分析中，研究人员发现与CD相关的UGI狭窄患者进行EBD是手术的有效替代方案，具有较高的短期技术和临床成功率，一般的长期疗效以及可接受的并发症发生率。